Post Content
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best Japanese stocks to buy right now. On April 6, Denali Therapeutics said Takeda Pharmaceutical Company Limited (NYSE:TAK) is ending its collaboration on DNL 593.
The two companies were working on developing the investigational therapy for frontotemporal dementia caused by granulin gene mutations. The candidate drug leverages Denali’s Protein Transport Vehicle technology to deliver progranulin across the blood-brain barrier. Takeda Pharmaceuticals terminated the collaboration for strategic reasons, not due to efficacy or safety concerns.
Takeda has embarked on a restructuring drive to streamline its operations and bankroll upcoming drug launches and its late-stage pipeline. The company has set its sights on $1.26 billion in annual gross savings by 2028 as part of the restructuring drive. The initiative is part of the next step in the company’s transformation under a new business structure unveiled early in the year that seeks to enhance operational efficiency.
Takeda Pharmaceutical Company Limited (NYSE:TAK) is a global, R&D-driven biopharmaceutical leader headquartered in Japan that discovers, develops, and delivers life-transforming treatments. It focuses on five core therapeutic areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience, plus targeted investments in Vaccines.
While we acknowledge the potential of TAK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 8 Best Lidar Stocks to Buy According to Analysts and 10 Best Cryptocurrency Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.